Acadia Healthcare Raises 2025 EBITDA Guidance to $675M–$700M Amid Rapid Bed Growth and Medicaid Shifts

Key Highlights from Acadia Healthcare's Q2 2025 Earnings Call

Acadia Healthcare Company, Inc. (ACHC) delivered a strong performance in the second quarter of 2025, showcasing solid top-line growth and strategic progress. The company reported total revenue of $869.2 million, marking a 9.2% increase compared to the same period last year. Adjusted EBITDA reached $201.8 million, reflecting a 7.5% year-over-year growth. This performance was driven by a combination of operational efficiency and continued expansion efforts.

CEO Christopher Howal Hunter emphasized the company’s resilience amid evolving market conditions. He highlighted the impact of the recently passed One Big Beautiful Bill Act, noting that its provisions are manageable due to carve-outs from work requirements and an extended timeline for implementing changes to Medicaid supplemental payments. For 2025, gross revenue from state Medicaid supplemental programs is expected to reach approximately $230 million, with potential reductions starting in fiscal 2028 if proposed changes are enacted.

Strategic Expansion and Operational Progress

Acadia Healthcare made significant strides in expanding its footprint across the U.S. The company approved a new Directed Payment Program in Tennessee, which is seen as a meaningful step in the broader national movement to invest in behavioral health programs. In Q2, 101 beds were added to existing facilities, bringing the year-to-date total to 479 beds. Additionally, three new joint venture facilities were completed, and the company now operates 174 comprehensive treatment centers (CTCs) across 33 states.

Despite these positive developments, Hunter noted that same-facility patient days increased by 1.8%, slightly below expectations. This was primarily attributed to weaker Medicaid volumes in acute care. However, commercial and Medicare volumes saw notable growth, rising by 9% and 8%, respectively. Hunter acknowledged the challenges in the Medicaid segment but remained optimistic about the long-term outlook.

Financial Performance and Outlook

The financial results for Q2 2025 showed a clear upward trend. Revenue reached $869.2 million, a 9.2% increase over the second quarter of the previous year. Adjusted EBITDA for the quarter was $201.8 million, resulting in an adjusted EBITDA margin of 23.2%. CFO Heather Dixon highlighted a favorable pretax benefit of $51.8 million from the Tennessee Supplemental Payment Program and start-up losses of $14.2 million from newly opened facilities.

Looking ahead, the company updated its full-year adjusted EBITDA guidance to a range of $675 million to $700 million. This adjustment reflects lower expected volume growth and higher start-up costs, partially offset by increased supplemental payments. Same-facility volume growth is now expected in the 2% to 3% range, down from previous guidance of low to mid-single digits. Start-up losses are anticipated at $60 million to $65 million, an increase of $10 million due to faster-than-expected bed openings.

Operational Challenges and Management Response

Management acknowledged several challenges during the earnings call. The primary driver of volume coming in below expectations was weaker Medicaid volumes in the acute care business. Hunter attributed this to evolving utilization patterns among managed Medicaid plans. Analysts also raised concerns about higher start-up losses, which Dixon explained were due to an accelerated opening pace. These incremental costs were experienced earlier in the year than previously anticipated.

In response to questions about free cash flow, Hunter mentioned the opportunity to pause some expansion capital spending, aiming to accelerate the path to becoming free cash flow positive. On the topic of wage trends and government investigations, Dixon noted a reduction in premium costs, currently around the 3.5% range. She also mentioned that legal costs associated with the investigation are expected to decrease in the second half of the year.

Risk Factors and Future Outlook

Management identified several ongoing risks, including weaker Medicaid volumes in acute care, local market pressures on specific facilities, and evolving payer utilization patterns. Hunter noted that these dynamics appear to be impacting admissions trends. The start-up losses from accelerated bed expansion and the additional drag from underperforming facilities were also highlighted as challenges.

Analysts raised concerns about the potential long-term impact of the One Big Beautiful Bill Act, as well as government investigation costs and capital allocation strategies. Despite these concerns, management maintained a confident but cautious tone, emphasizing ongoing monitoring, quality investments, and portfolio optimization.

Conclusion

Acadia Healthcare's Q2 2025 earnings call underscored the company's commitment to growth, despite facing headwinds from Medicaid policy changes and operational challenges. With a focus on quality care, technological innovation, and strategic expansion, the company is positioning itself to navigate the evolving healthcare landscape effectively. The transition to a new CFO, along with continued efforts in portfolio optimization, highlights Acadia's proactive approach to managing risks and capitalizing on opportunities.